Moreover, we attained this discovery when we analyzed the patients with DM in subgroups defined by the specific DPP-4 inhibitor prescribed, namely sitagliptin, saxagliptin, linagliptin, or vildagliptin. This evidence concerns the gene DPP4 and diabetes mellitus.